Ashish Kamat, MD, FACS

Director, Urologic Oncology Fellowship Program
Endowed Professor, Urology & Cancer Biology
University of Texas – MD Anderson Cancer Center 

Department of Urology (Unit 1373), CPB7.3269
1155 Pressler Street,  Houston, TX 77030
Tel: 713-792-3250; Fax: 713-794-4824


Dr Ashish M. Kamat is an Tenured Professor and Attending Surgeon in the Department of Urology at M.D. Anderson Cancer Center in Houston, TX.  He is also the Director of the Urologic Oncology Fellowship Program.

Dr Kamat’s area of expertise is in urologic oncology. He has a special interest in bladder and prostate cancer with an emphasis on organ sparing therapies, minimally invasive techniques (e.g. robotic surgery) and orthotopic bladder substitution (neobladder). While he is a busy clinically active surgeon, he maintains an active research portfolio in order to improve the care of patients. In the clinical arena, in concert with efforts to develop novel therapies, Dr Kamat’s efforts are directed towards identifying predictors of response to therapy, as a first step towards personalized cancer therapeutics. A major focus of his laboratory research is to develop novel therapies for bladder cancer using an approach which encompasses novel use of existing agents, the identification or novel targets and therapies, or a combination of these strategies.

Dr Kamat has authored numerous editorials and over 200 publications in prestigious peer reviewed journals, serves on the editorial board of Expert Reviews in Anticancer Therapy and is listed in 'Who's Who in Medicine' and ‘Best Doctors in America’. His basic, translational and clinical research is funded by peer-reviewed awards including from the National Cancer Institute. He serves as project PI on the MD Anderson Cancer Center GU (Bladder) SPORE, which is the only one of its kinds in the country. He has served on the NCI Bladder Cancer task force, on Grant Review Committees such as NIH-RO1 study sections as well as for international societies (Dutch Cancer Society and NIH – Singapore).

Dr Kamat is an active member of the urologic community, and a graduate of the AUA Leadership Program. He is also is active in many cancer support groups for patients such as the Bladder WebCafe and Bladder Cancer Advocacy Network (BCAN).



  1. Distinctions in Forensic Medicine and Medical Jurisprudence, Pharmacology,Microbiology, Biochemistry and Preventive and Social Medicine, University of Bombay, 1991
  2. Gold Medal Performance, University of Bombay, 1991 
  3. Manorama Vijayrat Hazarat Prize for Highest Cumulative Score, University of Bombay, 1991 
  4. Seth Khimchand Amulakh Prize for Excellence in Pharmacology, University of Bombay, 1991
  5. Shamdasani Foundation Scholarship for Standing First in University, University of Bombay, 1991
  6. Dr. L. H. Hiranandani Scholarship in Otorhinolaryngology, University of Bombay, 1992
  7. Best Paper, West Virginia University, 1997
  8. First Prize, American College of Surgeons, 1999
  9. First Prize, West Virginia University, 1999
  10. Scholars in Urology, Pfizer, 1999
  11. Second prize, University of Pittsburgh, 1999
  12. Best Published Papers in "Urology," AUA, 2000
  13. First Prize, American College of Surgeons, 2000
  14. Outstanding Laparoendoscopist, Society of Laparoendoscopic Surgeons, 2001
  15. Scholar in Training Award, American Association for Cancer Research, 2002
  16. Bladder SPORE Developmental Research Program Award, 2003
  17. Faculty Award, AACR, 2004
  18. Who's Who in America, 2005-present
  19. Excellent Reviewer Award, UT MD Anderson Cancer Center, 2007
  20. AUA Leadership Program Award, American Urological Association, 2008


Articles in Peer-Reviewed Journals  

  1. Kamat AM, Lamm DL. Chemoprevention of urological cancer. J Urol 161(6)(6):1748-60, 1999.
  2. Kamat AM, Hrabovsky EE. Imperforate anus: an unusual presentation of a common disease. W V Med J 95(6)(6):305-6, 1999.
  3. Kamat AM, DeHaven JI, Lamm DL. Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Urology 54(1)(1):56-61, 1999.
  4. Kamat AM, York T, DeBord J. Anastomotic fistula after ileal loop urinary diversion presenting as persistent urethral drainage. J Urol 165(3):906-907, 2001.
  5. Rosser CJ, Kuban DA, Levy LB, Pettaway CA, Chichakli R, Kamat AM, Sanchez-Ortiz RF, Pisters LL. Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy. J Urol 170(5)(5):1856-9, 2003.
  6. Kamat AM, Babaian K, Cheung MR, Naya Y, Huang SH, Kuban D, Babaian RJ. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. J Urol 170(5)(5):1860-3, 2003.
  7. Karashima T, Sweeney P, Kamat A, Huang S, Kim SJ, Bar-Eli M, McConkey DJ,. Nuclear factor-kappaB mediates angiogenesis and metastasis of human. Clin Cancer Res 9(7):2786-2797, 2003.
  8. Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Pisters PW, Guitreau DP, Pisters LL. Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 170(5)(5):1868-71, 2003.
  9. Kamat AM, Lamm DL. Antitumor activity of common antibiotics against superficial bladder cancer. Urology 63(3)(3):457-60, 2004.
  10. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell 6(2)(2):111-6, 2004.
  11. Kamat AM, Plager C, Tamboli P, Tran N, Pettaway CA. Metastatic epithelioid hemangioendothelioma of the penis managed with surgery and interferon-alpha. J Urol 171(5)(5):1886-7, 2004.
  12. Kamat AM, Shock RP, Naya Y, Rosser CJ, Slaton JW, Pisters LL. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 63(1)(1):46-50, 2004.
  13. Rosser CJ, Kuban DA, Lee SJ, Levy LB, Pettaway C, Kamat AM, Chichakli R, Lee A, Cheung RM, Sanchez-Ortiz R, Pisters LL. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc 96(7)(7):939-44, 2004.
  14. Kamat AM, Rosser CJ, Levy LB, Chichakli R, Lee AK, Cheung MR, Pisters LL. Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure. Urology 63(6)(6):1132-7, 2004.
  15. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 3(3)(3):279-90, 2004.
  16. Cheung R, Tucker SL, Lee AL, Dong L, Kamat A, Pisters L, Kuban DA. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol 61(1):14-19, 2005.
  17. Kamat AM, Nelkin GM. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology 66(6)(6):1209-12, 2005.
  18. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 17496)(6):2186-90, 2005.
  19. Shapiro A, Vakar F, Kamat AM. Diffuse granulomatous mesenteric disease caused by intravesical bacillus Calmette-Guerin instillation masquerading as peritoneal carcinomatosis. Urol Oncol 23(5)(5):352-3, 2005.
  20. Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with. Int J Radiat Oncol Biol Phys. 61(4):993-1002, 2005.
  21. Rosser CJ, Kamat AM, Wang X, Do KA, Sanchez-Ortiz RF, Kuban DA, Lee AK, Cheung R, Chichakli R, Pisters LL. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? Urology 66(2)(2):327-31, 2005.
  22. Kamat AM, Carpenter SM, Czerniak BA, Pisters LL. Metastatic penile cancer in a young Caucasian male: impact of delayed diagnosis. Urol Oncol 23(2)(2):130-1, 2005.
  23. Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker SL, Pisters L, Babaian RJ, Kuban D. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 63(1)(1):134-40, 2005.
  24. Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe. The vascular-targeting fusion toxin VEGF(121)/rGel. Neoplasia 7(10):912-920, 2005.
  25. Leibovici D, Kamat AM, Do KA, Pettaway CA, Ng CS, Evans RB, Rodriguez-Bigas M, Skibber J, Wang X, Pisters LL. Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer. Prostate 62(1)(1):101-4, 2005.
  26. Kamat AM, Jacobsohn KM, Troncoso P, Shen Y, Wen S, Babaian RJ. Validation of criteria used to predict extraprostatic cancer extension: a tool for use in selecting patients for nerve sparing radical prostatectomy. J Urol 174(4)(4 Pt 1):1262-5, 2005.
  27. Rosser CJ, Kamat AM, Pendleton J, Robinson TL, Pisters LL, Swanson DA, Babaian RJ. Impact of fellowship training on pathologic outcomes and complication rates of radical prostatectomy. Cancer 107(1):54-9, 7/1/2006.
  28. Metwalli AR, Kamat AM. Controversial issues and optimal management of stage T1G3 bladder cancer. Expert Rev Anticancer Ther 6(8):1283-94, 8/2006.
  29. Kamat AM, Dinney CP. A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer. Nat Clin Pract Urol 3(9):472-3, 9/2006.
  30. Rosser CJ, Kamat AM, Wang X, Do KA, Naya Y, Hoover DC, Troncoso P, Sanches-Ortiz RF, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology 67(4)(4):769-73, 2006.
  31. Busby JE, Kamat AM. Chemoprevention for bladder cancer. J Urol 176(5)(5):1914-20, 2006.
  32. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, Dinney CP, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol 176(4)(4 Pt 1):1463-7, 2006.
  33. Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 5(12):3032-41, 2006.
  34. Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, Kamat AM. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol 176(1)(1):53-7; discussion 57, 2006.
  35. Spiess PE, Kassouf W, Brown G, Highshaw R, Wang X, Do KA, Kamat AM, Czerniak B, Dinney CP, Grossman HB. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology 67(3)(3):466-71, 2006.
  36. Rosser CJ, Kamat AM, Pendleton J, Robinson T, Pisters LL, Swanson DA, Babaian. Impact of fellowship training on pathologic outcomes and complication rates of. Cancer 107(1):54-59, 2006.
  37. Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, Pisters LL, Lee AK, Rosser CJ, Kuban DA. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 107(3)(3):631-9, 2006.
  38. Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM. Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res 66(1)(1):412-8, 2006.
  39. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int 98(6)(6):1176-80, 2006.
  40. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 175(6)(6):2058-62, 2006.
  41. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 107(7)(7):1483-90, 2006.
  42. Kassouf W, Leibovici D, Luongo T, Munsell MF, Vakar F, Dinney CP, Grossman HB, Kamat AM. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer 107(7)(7):1491-5, 2006.
  43. Canfield SE, Kamat AM, Sánchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 175(6)(3 Pt 1):864-9, 2006.
  44. Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, Pisters LL. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175(3)(3 Pt 1):881-5, 2006.
  45. Dhanani NN, Kamat AM. Treatment of bladder cancer in cardiac transplant patients. Int Urol Nephrol 38(3-4)(3-4):477-9, 2006.
  46. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF. Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology 67(3)(3):518-23, 2006.
  47. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer 107(7)(7):1503-10, 2006.
  48. Kassouf W, Highshaw R, Nelkin GM, Dinney CP, Kamat AM. Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. J Urol 176(4)(4 Pt 1):1642-7, 2006.
  49. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110(1):62-7, 7/1/2007.
  50. Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer 110(4):764-9, 8/15/2007.
  51. Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther 6(3):1022-30, 3/2007.
  52. Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM, Pisters LL. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol 177(4):1330-4; discussion 1334, 4/2007.
  53. Brown GA, Matin SF, Busby JE, Dinney CP, Grossman HB, Pettaway CA, Munsell MF, Kamat AM. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology 70(2):252-6, 8/2007.
  54. Caraway NP, Khanna A, Payne L, Kamat AM, Katz RL. Combination of cytologic evaluation and quantitative digital cytometry is reliable in detecting recurrent disease in patients with urinary diversions. Cancer 111(5)(5):323-329. e-Pub 8/2007, 10/2007.
  55. Chen M, Kamat AM, Huang M, Grossman HB, Dinney CP, Lerner SP, Wu X, Gu J. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis 28(10)(10):2160-2165. e-Pub 8/2007, 10/2007.
  56. Jhamb M, Lin J, Ballow R, Kamat AM, Grossman HB, Wu X. Urinary tract diseases and bladder cancer risk: a case-control study. Cancer Causes Control 18(8):839-45, 10/2007.
  57. Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, Lin DW. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol 178(6)(6):2302-2306. e-Pub 10/2007, 12/2007.
  58. Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer 110(12)(12):2700-2708, 12/2007.
  59. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110(1):62-67, 2007.
  60. Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, Dinney CP, Kamat AM. P0 Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. Eur Urol 52(3)(3):769-776, 2007.
  61. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol 177(1)(1):131-8, 2007.
  62. Spiess PE, Kassouf W, Steinberg JR, Tuziak T, Hernandez M, Tibbs RF, Czerniak B, Kamat AM, Dinney CP, Grossman HB. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol 25(1)(1):38-45, 2007.
  63. Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM,. Surgical management of growing teratoma syndrome: The M. D. Anderson Experience. J Urol 77(4):1330-4, 2007.
  64. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM. Malignant transformation of testicular teratoma: A chemoresistant phenotype. Urol Oncol, 1/11/2008.
  65. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP 3rd, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III Prevention Trial of Fenretinide in Patients with Resected Non Muscle-Invasive Bladder Cancer. Clin Cancer Res. 14(1):224-229, 1/2008.
  66. Kassouf W, Spiess PE, Brown GA, Liu P, Grossman HB, Dinney CP, Kamat AM. Prostatic Urethral Biopsy Has Limited Usefulness in Counseling Patients Regarding Final Urethral Margin Status During Orthotopic Neobladder Reconstruction. J Urol 180(1):164-7; discussion 167, 5/2008.

Invited Articles

  1. Kamat AM, Lamm DL. Intravesical therapy for superficial bladder cancer. Inf Urol 12(2):37-45, 1999.
  2. Kamat AM, Lamm DL. Role of BCG in treatment of superficial bladder cancer. Indian Journal of Urology 16(1):1-9, 1999.
  3. Kamat AM, Lamm DL. Current trends in intravesical therapy for bladder cancer. Contemporary Urology 12(8):64-88, 2000.
  4. Kamat AM, Lamm DL. Diet and nutrition in urologic cancer. W V Med J 96(3)(3):449-454, 2000.
  5. Kamat AM, Lamm DL. Intravesical therapy for bladder cancer. Urology 55(2)(2):161-168, 2000.
  6. Kamat AM, Lamm DL. Immunotherapy for bladder cancer. Curr Urol Rep 2(1)(1):62-69, 2001.
  7. Kamat AM, Lamm DL. Chemoprevention of bladder cancer. Urol Clin North Am 29(1)(1):1-12, 2002.
  8. Kamat AM. Chemoprevention of superficial bladder cancer. Expert Rev Anticancer Ther 3(6)(6):799-808, 2003.
  9. Kamat AM, Dinney CPN. Molecular aspects of metastases in bladder cancer. Urol Integ 8(2):180-189, 2003.
  10. Kassouf W, Kamat AM. Current state of immunotherapy for bladder cancer. Expert Rev Anticancer Ther 4(6)(6):1283-1294, 2004.
  11. Herring JC, Kamat AM. Treatment of muscle-invasive bladder cancer: progress and new challenges. Expert Rev Anticancer Ther 4(6)(6):1047-1056, 2004.
  12. Brassell SA, Kamat AM. Contemporary Intravesical Treatment Options for Urothelial Carcinoma of the bladder. J Natl Compr Canc Netw 4(10)(10):1027-1036, 2006.
  13. Metwalli A, Kamat AM. Controversies and optimal management of T1G3 bladder cancer. Expert Rev Anticancer Ther 6(8):1283-94, 2006.
  14. Agarwal PK, Black PC, Kamat AM. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol 26(1):39-44, 2/1/2008. e-Pub



    1. Kamat AM. Neoadjuvant chemotherapy for invasive bladder cancer: a new standard of care? Am J Clin Onc Rev 2(11):624-637, 2003.
    2. Kamat AM. Outcome of penile cancer in circumcised men. J Urol 175(2):561, 2006.
    3. Kamat AM, Dinney CP. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Nat Clin Pract Urol 3(9):472-473, 2006.
    4. Kamat AM, Fisher MB. Lymph node density: surrogate marker for quality of resection in bladder cancer? Expert Rev Anticancer Ther 7(6):777-9, 2007.
    5. Kamat AM. Intravesical BCG for bladder cancer: how much is enough? Cancer 113(4):674-6, 8/2008.